Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer

This review of 2 RCTs (n=2201) found abiraterone with androgen deprivation therapy (ADT) improves survival but probably not QOL. It probably also extends disease‐specific survival and delays disease progression vs ADT alone. Risk of grades III to V adverse events is increased.

Source:

Cochrane Database of Systematic Reviews